UK pharmaceutical wholesaler AAH Holdings has been told, after a Monopolies and Mergers Commission report, that it must divest some of its business, which expanded with the acquisition of Medicopharma NV, because this has stifled competition.
The Commission reportedly concluded that last year's takeover of the Medico-pharma operations led to a reduction in competition in the Grampian and High-land regions of Scotland. However, it did not believe that competition would be affected significantly at the national level. It has suggested that AAH should divest a business which is as close as possible to that carried on by Medicopharma UK (pre-takeover) from its Aberdeen depot.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze